LON:ERGO - Ergomed plc (ERGO.L) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 980
▼ -30 (-2.97%)
1 month | 3 months | 12 months
Get New Ergomed plc (ERGO.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ERGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ERGO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Ergomed plc (ERGO.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 980.
N/A
The current consensus among 0 investment analysts is to n/a stock in Ergomed plc (ERGO.L). This rating has held steady since May 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/5/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
6/13/2019Numis SecuritiesReiterated RatingBuy
i
5/16/2019Numis SecuritiesReiterated RatingBuyGBX 190 ➝ GBX 267
i
4/10/2019Numis SecuritiesUpgradeBuyGBX 230
i
9/19/2018Numis SecuritiesUpgradeAddGBX 190
i
6/28/2018Numis SecuritiesDowngradeHoldGBX 300 ➝ GBX 250
i
4/11/2018Numis SecuritiesReiterated RatingBuyGBX 300
i
3/5/2018Numis SecuritiesReiterated RatingBuyGBX 300
i
2/1/2018Numis SecuritiesReiterated RatingBuyGBX 300
i
1/25/2018Numis SecuritiesReiterated RatingBuyGBX 300
i
12/15/2017N+1 SingerReiterated RatingCorporate
i
10/23/2017Numis SecuritiesBoost Price TargetBuyGBX 280 ➝ GBX 300
i
10/6/2017Numis SecuritiesReiterated RatingBuyGBX 280
i
9/19/2017Numis SecuritiesReiterated RatingBuyGBX 275
i
5/2/2017Stifel NicolausLower Price TargetBuyGBX 315 ➝ GBX 304
i
5/2/2017Numis SecuritiesLower Price TargetBuyGBX 300 ➝ GBX 275
i
4/21/2017N+1 SingerBoost Price TargetBuyGBX 293 ➝ GBX 360
i
4/4/2017Numis SecuritiesReiterated RatingBuyGBX 300
i
4/4/2017Stifel NicolausReiterated RatingBuyGBX 315
i
3/20/2017Stifel NicolausReiterated RatingBuyGBX 315
i
3/20/2017Numis SecuritiesReiterated RatingBuyGBX 277
i
2/6/2017Stifel NicolausBoost Price TargetBuyGBX 300 ➝ GBX 315
i
2/6/2017Numis SecuritiesReiterated RatingBuyGBX 277
i
2/3/2017N+1 SingerReiterated RatingBuyGBX 293
i
1/17/2017Numis SecuritiesReiterated RatingBuyGBX 267
i
11/29/2016N+1 SingerReiterated RatingBuyGBX 275
i
11/29/2016Numis SecuritiesReiterated RatingBuyGBX 267
i
11/7/2016N+1 SingerBoost Price TargetBuyGBX 265 ➝ GBX 275
i
11/1/2016N+1 SingerReiterated RatingBuy
i
11/1/2016Stifel NicolausReiterated RatingBuyGBX 271
i
11/1/2016Numis SecuritiesReiterated RatingBuyGBX 267
i
10/21/2016N+1 SingerBoost Price TargetBuyGBX 263 ➝ GBX 265
i
10/17/2016Numis SecuritiesReiterated RatingBuyGBX 267
i
9/26/2016N+1 SingerReiterated RatingBuy
i
9/22/2016Stifel NicolausReiterated RatingBuyGBX 271
i
9/2/2016Stifel NicolausReiterated RatingBuyGBX 271
i
2/1/2016Stifel NicolausReiterated RatingBuyGBX 281
i
(Data available from 1/26/2016 forward)
Ergomed plc (ERGO.L) logo
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Read More

Today's Range

Now: GBX 980
980
1,030

50 Day Range

MA: GBX 1,033.50
930
1,200

52 Week Range

Now: GBX 980
258
1,230

Volume

65,445 shs

Average Volume

130,153 shs

Market Capitalization

£477.45 million

P/E Ratio

78.40

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ergomed plc (ERGO.L)?

The following Wall Street research analysts have issued reports on Ergomed plc (ERGO.L) in the last year:

What is the current price target for Ergomed plc (ERGO.L)?

0 Wall Street analysts have set twelve-month price targets for Ergomed plc (ERGO.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for Ergomed plc (ERGO.L) in the next year.

What is the current consensus analyst rating for Ergomed plc (ERGO.L)?

Ergomed plc (ERGO.L) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."

What other companies compete with Ergomed plc (ERGO.L)?

How do I contact Ergomed plc (ERGO.L)'s investor relations team?

Ergomed plc (ERGO.L)'s physical mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company's listed phone number is +44-1483-503205. The official website for Ergomed plc (ERGO.L) is www.ergomedplc.com.